Abstract
Benzydamine is a topical anti-inflammatory drug which is widely available and used topically for the treatment of the mouth. It is also used as a gel for application to inflamed joints. It has physicochemical properties and pharmacological activities which differ markedly from those of the aspirin-line non-steroidal anti-inflammatory drugs. Benzydamine is a weak base unlike the aspirin-like drugs which are acids or metabolized to acids. A major contrast with the aspirin-like drugs is that benzydamine is a weak inhibitor of the synthesis of prostaglandins but it has several properties which may contribute to its anti-inflammatory activity. These properties include inhibition of the synthesis of the inflammatory cytokine, tumour necrosis factor-α (EC50, 25 µmol/L). Inhibition of the oxidative burst of neutrophils occurs under some conditions at concentrations of 30 to 100 µmol/L, concentrations which may be produced within oral tissues after local application. A further activity of benzydamine is a general activity known as membrane stabilization which is demonstrated by several actions including inhibition of granule release from neutrophils at concentrations ranging from 3 to 30 µmol/L and stabilization of lysosomes. Lack of knowledge of the tissue concentrations of benzydamine limit the correlation between pharmacological activities in vitro and in vivo. The concentration of benzydamine in the mouthwash is 4 mmol/L but the concentrations in oral tissues have not been studied adequately. Limited data in the rat indicates that concentrations of benzydamine in oral tissues are approximately 100 µmol/L.
Similar content being viewed by others
References
Silvestrini B, Scorza Barcellona P, Garau A, Catanese B. Toxicology of benzydamine. Toxicol Appl Pharmacol. 1967;10:148–59.
Hansch C, Sammes PG, Taylor JB. In: Drayton CJ, ed. Comprehensive Medicinal Chemistry, Volume 6. Oxford: Pergamon Press; 1990:309.
Jez JM, Vanderkooi JM, Laties AM. Spectroscopic characterization of benzdazac and benzydamine: possible photochemical modes of action. Biochem Biophys Res Commun. 1996;221:266–70.
Baldock GA, Brodie RR, Chasseaud LF, Taylor T, Walmsley LM, Catanese B. Pharmacokinetics of benzydamine after intravenous, oral, and topical doses to human subjects. Biopharm Drug Dispos. 1991;12:481–92.
Schoenwald RD, Kumakura T, Catanese B. Pharmacokinetics of benzydamine. Int J Tiss React. 1987;9:9–7.
Beckett AH, Triggs EJ. Buccal absorption of basic drugs and its application as an in vivo model of passive drug transfer through lipid membranes. J Pharm Pharmacol. 1967;19:31S-41S.
Bickel MH, Weder HJ. Buccal absorption and other properties of pharmacokinetic importance of imipramine and its metabolites. J Pharm Pharmacol. 1969;21:160–8.
Chasseaud LF, Catanese B. Pharmacokinetics of benzydamine. Int J Tiss React. 1985;7:195–204.
Andersson K, Larsson H. Percutaneous absorption of benzydamine in guinea pig and man. Arzneimittelforschung. 1974;24:1686–8.
Lisciani R, Scorza Barcellona P, Silvestrini B. Researches on the topical activity of benzydamine. Eur J Pharmacol. 1968;3:157–62.
Giacalone E, Valzelli L. A method for the determination of 1-benzyl-3[3′-(dimethylamino) propoxy]-1H-indazole (benzydamine) in rat tissues. Med Pharmacol Exp. 1966;15:102–6.
Kataoka S, Nishimura K, Naito T. In vivo metabolism and anti-inflammatory activity of benzydamine hydrochloride in rats treated with carrageenin. Chem Pharm Bull (Tokyo). 1979;27:2890–903.
Catanese B, Lisciani R, Piccinelli D. Erythrocyte membrane stabilization and protein binding of some anti-inflammatory drugs and of deoxycholic acid. Biochem Pharmacol. 1969;18:1707–10.
Benedetto A, Cassone A, Amici C, Garaci E. Enhanced uptake of actinomycin D in cultured mammalian cells by the anti-inflammatory non-steroidal drug benzydamine. Biochem Pharmacol. 1979;28:2723–8.
Catanese B, Grasso A, Silvestrini B. Studies on the absorption and elimination of benzydamine in the mouse, rat, dog and man. Arzneimittelforschung. 1985;35:634–5.
Köppel C, Tenczer. Metabolism of benzydamine. Arzneimittelforschung. 1985;35:634–5.
Fanaki NH, El-Nakeeb MA. Antibacterial activity of benzydamine and antibiotic-benzydamine combinations against multifold resistant clinical isolates. Arzneimittelforschung. 1996;46:320–3.
Fanaki NH, el-Nakeeb MA. Antimicrobial activity of benzydamine, a non-steroid anti-inflammatory agent. J Chemother. 1992;4:347–52.
White SK. The pharmacology of benzydamine. Res Clin Forums. 1988;10:8–23.
Boissier JR, Lwoff JM, Hertz F. Action comparee de six anti-inflammatory non steroidiques. Therapie. 1970;25:43–60.
Yamatake Y, Kato H, Takagi K. Effects of vasoactive agents on the canine forelimb venous perfusion preparation and their modification by anti-inflammatory drugs. Jpn J Pharmacol. 1975;25:129–39.
Fantato S, De Gregorio M. Clinical evaluation of topical benzydamine in traumatology. Arzneimittelforschung. 1971;21:1530–3.
Chatterjee DS. A double blind clinical study with benzydamine 3% on soft tissue injuries in an occupational health centre. J Int Med Res. 1977;5:450–8.
Froom J, Boisseau V. Benzydamine oral rinse for sore throat. Curr Ther Res. 1979;26:856–61.
Whiteside MW. A controlled study of benzydamine oral rinse (“Difflam”) in general practice. Curr Med Res Opin. 1982;8:188–90.
Epstein JB, Stevenson-Moore P. Benzydamine hydrochloride in prevention and management of pain in oral mucositis associated with radiation therapy. Oral Surg Oral Med Oral Pathol. 1986;62:145–8.
Sonis ST, Clairmont ST, Lockhart PB, Connolly SF. Benzydamine HCl in the management of chemotherapy-induced mucositis. I. Pilot study. J Oral Med. 1985;40:67–71.
Valijan A. Pain relief after tonsillectomy. Anaesthesia. 1989;44:990–1.
Matthews RW, Scully CM, Levers BGH. Clinical evaluation of benzydamine, chlorohexidine, and placebo mouthwashes in the management of recurrent aphthous stomatis. Oral Surg Oral Med Oral Pathol. 1987;63:189–91.
Hunter KMacD. A clinical evaluation of benzydamine hydrochloride. Aust Dent J. 1978;23:164–6.
Adame Sosa R, Gomez Pedroso A. Evaluation of benzydamine in treatment of secondary inflammation following extraction of third molars. Pract Odontol. 1990;11:29–31.
Tomazzoli L, Bonora MR, Luparini L, Durando MG, Ciolo V, Bonomi L. Effects of benzydamine on the rabbit’s eye reaction to surgical, physical and chemical stimuli. J Ocul Pharmacol. 1989;5:71–80.
Saeed SA, Kendall PA, Butt NM, Collier HOJ. On the mode of action and biochemical properties of anti-inflammatory drugs. Biochem Soc Trans. 1979;7:655–7.
Müller-Peddinghaus R, Wurl M, Lenoir G, Houben A, Remacle J. Einfluss von benzydamin auf bildung ung interacktion von reaktiven sauerstoffspezies und die zyklo- und lipoxigenase. Arzneimittelforschung. 1987;37:601–5.
Segre G, Hammarström S. Aspects of the mechanisms of action of benzydamine. Int J Tiss React. 1985;7:187–93.
Rang HP, Dale MM, Ritter JM. In: Pharmacology, 3rd edn. Edinburgh: Churchill Livingstone; 1995:230.
Löffler BM, Bohn E, Hesse B, Kunze H. The action of benzydamine on phospholipase activation. Arzneimittelforschung. 1987;37:618–21.
Moncada S, Needleman P, Bunting S, Vane JR. Prostaglandin endoperoxide and thromboxane generating systems and their selective inhibition. Prostaglandins. 1976;12:323–35.
Diczfalusy U, Hammarström S. Inhibitors of thromboxane synthase in human platelets. FEBS Lett. 1977;82:107–10.
Jansen WCM. Antithrombotische wirking von benzydamin. Arzneimittelforschung. 1987;37:626–8.
Flower RJ, Cheung HS, Cushman DW. Quantitative determination of prostaglandins and malondialdehyde formed by the arachidonic oxygenase (prostaglandin synthetase) system of bovine seminal vesicle. Prostaglandins. 1973;4:325–41.
Dinnendahl V, Peters HD, Schönhöfer PS. Effects of benzydamine on the lipolytic system of fat cells. Biochem Pharmacol. 1976;25:299–303.
Akamatsu M, Miura Y. Inhibition of amino sugar formation by several non-steroid anti-inflammatory agents. Biochem Pharmacol. 1972;21:1991–3.
Baggiolini M, Mauderli P, Näf U, Catanese B. Effect of benzydamine on exocytosis and respiratory burst in human neutrophils and mononuclear phagocytes. Agents Actions. 1985;16:346–52.
Sironi M, Pozzi P, Polentarutti N et al. Inhibition of inflammatory cytokine production and protection against endotoxin toxicity by benzydamine. Cytokines. 1996;8:710–16.
Müller-Peddinghaus R, Wurl M. The amplified chemiluminescence test to characterize antirheumatic drugs as oxygen radical scavengers. Biochem Pharmacol. 1987;36:1125–32.
Oyanagui Y. Inhibition of superoxide anion production in macrophages by anti-inflammatory drugs. Biochem Pharmacol. 1976;25:1473–80.
Silvestrini B, Garau A, Pozzatti C, Cioli V, Catanese B. Additional pharmacological studies on benzydamine. Arch Int Pharmacodyn Ther. 1966;163:61–9.
Simard-Savoie S, Forest D. Topical anaesthetic activity of benzydamine. Curr Ther Res. 1978;6:734–5.
Cioli V, Corradino C, Scorza Barcellona P. Review of pharmacological data on benzydamine. Int J Tiss React. 1985;8:205–13.
Buritova J, Fletcher D, Honore P, Besson J-M. Effects of local anaesthetics on carrageenan-evoked inflammatory nocioceptive processing in the rat. Br J Anaesth. 1996;77:645–52.
Pedersen JL, Callesen T, Moiniche S, Kehlet H. Analgesic and anti-inflammatory effects of lignocaine-prilocaine (EMLA) cream in human burn injury. Br J Anaesth. 1996;76:806–10.
Goto K, Hisadome M, Imamura H. Effects of tinoridine on stability of rat liver and kidney lysosomes and liver parenchymal cells. Biochem Pharmacol. 1977;26:11–18.
Irita K, Fujita I, Takeshige S, Minakami S, Yoshitake J. Cinchocaine and amethocaine inhibit activation and activity of superoxide production of human neutrophils. Br J Anaesth. 1986;58:639–45.
Anderson R, Ramafi G, Theron AJ. Membrane stabilizing anti-oxidative interactions of propranolol and dexpropranolol with neutrophils. Biochem Pharmacol. 1996;52:341–9.
Neal TM, Vissers MC, Winterbourn CC. Inhibition of nonsteroidal anti-inflammatory drugs of superoxide production and granule enzyme release by polymorphonuclear leukocytes stimulated with immune complexes or formyl-methionyl-leucyl-phenylalanine. Biochem Pharmacol. 1987;36:2511–17.
Neal TM, Vissers MC, Winterbourn CC. Inhibition of neutrophil-mediated degradation of isolated basement membrane collagen by nonsteroidal antiinflammatory drugs that inhibit degranulation. Arthritis Rheum. 1987;30:908–13.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Quane, P.A., Graham, G.G. & Ziegler, J.B. Pharmacology of benzydamine. Inflammopharmacol 6, 95–107 (1998). https://doi.org/10.1007/s10787-998-0026-0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10787-998-0026-0